MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.biomaterials.2026.124396

Медицинская библиотека · Biomaterials · 2026

Programmable multivalent aptamer-drug conjugates enable stable tumor targeting and enhanced therapy for advanced bladder cancer.

Tao Shan, Zhong Yun, Ju Jiping, Sun Xiaofei, Guo Bin, Xia Qian, Chen Haige, Tian Tian, Tan Weihong, Lei Haozhi

СтатьяПеревод в очереди

Аннотация

The therapeutic potential of aptamer-drug conjugates (APDCs) is constrained by challenges in achieving high in vivo stability, strong target affinity, and binding robustness under blood flow-induced mechanical stress. To address these limitations, multivalent APDCs have been actively explored; however, most reported designs rely on heterogeneous assemblies, and their binding stability under mechanical perturbations remains poorly characterized. Here, we report a programmable and structurally defined multivalent APDC, termed Multi-MMAE, constructed via hybridization chain reaction (HCR)-mediated DNA assembly. This architecture enables tunable modulation of aptamer multivalency and drug incorporation, allowing multivalent presentation of both the PTK7-targeting aptamer Sgc-8 and the cytotoxic payload monomethyl auristatin E via a cleavable VC-PAB linker. Compared with monovalent Sgc-8-MMAE, Multi-MMAE exhibits enhanced serum stability, ∼11.5-fold higher binding affinity, improved binding stability under flow-mimicking perturbations, and increased cellular uptake and intracellular drug delivery. At equivalent MMAE doses, Multi-MMAE demonstrates superior antitumor efficacy and survival benefits in both orthotopic and experimental lung colonization bladder cancer mouse models, accompanied by prolonged circulation, enhanced tumor retention relative to Sgc-8-MMAE, and reduced systemic toxicity compared with free MMAE. Mechanistic studies further reveal that structural multivalency modulates intracellular trafficking pathways and pharmacodynamic behavior. Collectively, this work establishes a modular aptamer-drug conjugate strategy for advancing APDC-mediated cancer therapy.

Для цитирования: Tao Shan, Zhong Yun, Ju Jiping, Sun Xiaofei, Guo Bin, Xia Qian, Chen Haige, Tian Tian, Tan Weihong, Lei Haozhi. Programmable multivalent aptamer-drug conjugates enable stable tumor targeting and enhanced therapy for advanced bladder cancer.. Biomaterials. 2026. DOI: 10.1016/j.biomaterials.2026.124396.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.